Effect of supplementation on the treatment of migraine headaches

Phase 3

• Conditions: Migraine.; Migraine

• Registration Number: IRCT20191014045100N1
• Lead Sponsor: Oroumia University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 February 2020

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

Age range 18-55 years
female
Resident of Urmia
Having episodic or chronic migraines
Interested in collaborating in the study with a 3-month intervention

Exclusion Criteria

Use of any supplement or multivitamin - mineral in the last 3 months
Pregnancy
Breastfeeding
smoking
History of serious head trauma or head and neck surgery in the past 2 years
A history of vasculitis
Malignancies
AIDS
History of diabetes
History of stroke and coronary artery disease
Cardiovascular disease
Asthma
Rheumatoid Arthritis
Kidney or liver failure
kidney stone
Use of drugs that decrease lipid profile (total cholesterol, TG, LDL-C)
Taking non-steroidal anti-inflammatory drugs such as ibuprofen and naproxen (for more than 15 days per month in the last 3 months)
History of mental disorders such as depression
blood pressure
Digestive diseases
21. Lupus

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Frequency of migraine attacks. Timepoint: At baseline (before intervention) and 30, 60, and 90 days after starting zinc gluconate supplementation. Method of measurement: Monthly Notepad.;The severity of migraine attacks. Timepoint: At baseline (before intervention) and 30, 60 and 90 days after zinc gluconate supplementation. Method of measurement: Pain severity questionnaire NRS (Numeric Rating Scale).;The period of migraine attacks. Timepoint: At baseline (before intervention) and 30, 60 and 90 days after zinc gluconate supplementation. Method of measurement: Monthly Notepad.